Verrica Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

VRCA 12.09.2024

Full Press ReleaseSEC FilingsOur VRCA Tweets

About Gravity Analytica

Recent News

  • 01.21.2025 - Verrica Pharmaceuticals Announces Presentation of Three Posters Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2025 Winter Clinical Dermatology Conference
  • 12.20.2024 - Verrica Provides Business and Operational Update
  • 12.09.2024 - Verrica Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Recent Filings

  • 12.09.2024 - 4 Statement of changes in beneficial ownership of securities
  • 12.09.2024 - S-8 Securities to be offered to employees in employee benefit plans
  • 12.09.2024 - 8-K Current report
PDF Version

WEST CHESTER, Pa.,Dec. 09, 2024(GLOBE NEWSWIRE) --Verrica Pharmaceuticals Inc.(“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Verrica’s Compensation Committee grantedDavid Zawitz, Verrica’s new Chief Operating Officer, a nonqualified stock option to purchase 950,000 shares of its common stock under the Company’s Inducement Plan, effectiveDecember 9, 2024. The stock option was granted as a material inducement to Mr. Zawitz’s employment with Verrica in accordance with Nasdaq Listing Rule 5635(c)(4).

The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Verrica (or following a bona fide period of non-employment), as an inducement material to such individual’s entering into employment with Verrica, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.

The option award will have an exercise price equal to the closing price of Verrica’s common stock onDecember 9, 2024. The option award will vest and become exercisable as to 1/8th of the shares on the date that is six months following Mr. Zawitz’s start date, and 1/48th of the shares each month thereafter on the same day of the month as the start date, subject to Mr. Zawitz’s continuous service with Verrica on such vesting dates. The option award is subject to the terms and conditions of the Inducement Plan, and the terms and conditions of a stock option agreement covering the grant.

AboutVerrica Pharmaceuticals Inc.

Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica’s product YCANTH® (VP-102) (cantharidin), is the first and only commercially available treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people inthe United States, primarily children. YCANTH® (VP-102) is also in development to treat common warts and external genital warts, two of the largest remaining unmet needs in medical dermatology. Verrica is developing VP-103, its second cantharidin-based product candidate, for the treatment of plantar warts. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 (formerly LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. For more information, visitwww.verrica.com.

FOR MORE INFORMATION, PLEASE CONTACT:

Investors:

Kevin GardnerLifeSci Advisorskgardner@lifesciadvisors.com

Chris CalabreseLifeSci Advisorsccalabrese@lifesciadvisors.com

Primary Logo

Source: Verrica Pharmaceuticals Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com